

---

**THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION**

---

If you are in any doubt about the contents of this circular, you should consult your stockbroker or other registered securities dealer, bank, solicitor, accountant or other professional adviser immediately.

If you have sold or transferred your shares in Shenzhen Hepalink Pharmaceutical Group Co., Ltd., you should nevertheless immediately inform the person(s) to whom you sold or transferred the shares of the contents of this circular, so that they can also take appropriate action.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

---



( )  
(A joint stock company incorporated in the People's Republic of China with limited liability)  
(Stock code: 9989)

**2022 WORK REPORT OF THE BOARD OF DIRECTORS  
2022 WORK REPORT OF THE SUPERVISORY COMMITTEE  
2022 ANNUAL REPORT AND ITS SUMMARY,  
H SHARES RESULTS ANNOUNCEMENT,  
H SHARES 2022 ANNUAL REPORT, 2022 CORPORATE GOVERNANCE REPORT AND  
2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT  
2022 FINAL FINANCIAL REPORT  
2022 PROFIT DISTRIBUTION PROPOSAL  
RE-APPOINTMENT OF AUDITORS OF THE COMPANY  
ELECTION OF THE SIXTH SESSION OF THE BOARD  
REMUNERATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF  
THE SIXTH SESSION OF THE BOARD  
ELECTION OF THE SIXTH SESSION OF THE SUPERVISORY COMMITTEE  
PURCHASE OF WEALTH MANAGEMENT PRODUCTS AND CASH FLOW MANAGEMENT  
USING INTERNAL FUNDS  
APPLICATION FOR CREDIT LINE AND PROVIDING GUARANTEE TO CERTAIN BANKS FOR 2023  
AMENDMENT OF ARTICLES OF ASSOCIATION  
AND  
NOTICE OF THE 2022 ANNUAL GENERAL MEETING**

---

A meeting of the Board of Directors of the Company will be held on 3 November 2023 (AGM) at 2:30 p.m. (China Standard Time) on 22 November 2023 at the Company's head office, Room 3031, 30th Floor, Hepalink Building, No. 1000001, Xixiang Avenue, Xixiang, Shenzhen, P.R. China.

A meeting of the Supervisory Committee of the Company will be held on 3 November 2023 at 2:30 p.m. (China Standard Time) on 22 November 2023 at the Company's head office, Room 3031, 30th Floor, Hepalink Building, No. 1000001, Xixiang Avenue, Xixiang, Shenzhen, P.R. China.

A meeting of the 2022 Annual General Meeting of the Company will be held on 3 November 2023 at 2:30 p.m. (China Standard Time) on 22 November 2023 at the Company's head office, Room 3031, 30th Floor, Hepalink Building, No. 1000001, Xixiang Avenue, Xixiang, Shenzhen, P.R. China.

A meeting of the 2022 Annual General Meeting of the Company will be held on 3 November 2023 at 2:30 p.m. (China Standard Time) on 22 November 2023 at the Company's head office, Room 3031, 30th Floor, Hepalink Building, No. 1000001, Xixiang Avenue, Xixiang, Shenzhen, P.R. China.

---

# CONTENTS

---

	<i>P.</i>
<b>DEFINITIONS</b> .....	1
<b>LETTER FROM THE BOARD</b> .....	3
1. ....	4
2. ....	4
2022 .....	4
2022 .....	5
2022 Annual General Meeting, 2022 Annual General Meeting, 2022 Annual General Meeting, 2022 Annual General Meeting .....	5
2022 .....	5
2022 .....	5
.....	6
.....	6
.....	7
.....	7
.....	9
Annual General Meeting 2023 .....	9
Annual General Meeting, Annual General Meeting .....	9
3. Annual General Meeting .....	9
4. <input checked="" type="checkbox"/> .....	10
5. ....	11
<b>APPENDIX I – PROFILES OF THE PROPOSED SIXTH SESSION OF THE BOARD</b> ...	12
<b>APPENDIX II – AMENDMENT OF ARTICLES OF ASSOCIATION</b> .....	18
<b>NOTICE OF THE 2022 ANNUAL GENERAL MEETING</b> .....	20
<i>Notes</i> .....	20

---

## DEFINITIONS

---

*L* is a *...*

A *...*



---

LETTER FROM THE BOARD

---



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
( 深圳市海普瑞藥業集團股份有限公司 )  
(A joint stock company incorporated in the People's Republic of China with limited liability)  
(Stock code: 9989)

English: (C... B...)  
(D... G... M...)  
(G... M...)

P... C:  
21

Chinese: D...  
...  
...

P...  
H... K...  
4724, 471  
30  
K...

April 20, 2023

**2022 WORK REPORT OF THE BOARD OF DIRECTORS  
2022 WORK REPORT OF THE SUPERVISORY COMMITTEE  
2022 ANNUAL REPORT AND ITS SUMMARY,  
H SHARES RESULTS ANNOUNCEMENT,  
H SHARES 2022 ANNUAL REPORT,  
2022 CORPORATE GOVERNANCE REPORT AND  
2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT  
2022 FINAL FINANCIAL REPORT  
2022 PROFIT DISTRIBUTION PROPOSAL  
RE-APPOINTMENT OF AUDITORS OF THE COMPANY  
ELECTION OF THE SIXTH SESSION OF THE BOARD  
REMUNERATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF  
THE SIXTH SESSION OF THE BOARD  
ELECTION OF THE SIXTH SESSION OF THE SUPERVISORY COMMITTEE  
PURCHASE OF WEALTH MANAGEMENT PRODUCTS AND  
CASH FLOW MANAGEMENT  
USING INTERNAL FUNDS  
APPLICATION FOR CREDIT LINE AND PROVIDING GUARANTEE TO  
CERTAIN BANKS FOR 2023  
AMENDMENT OF ARTICLES OF ASSOCIATION**

---

# LETTER FROM THE BOARD

---

## 1. INTRODUCTION

The Board of Directors (the "Board") of The Bank of Montreal (the "Bank") is pleased to provide you with the following information regarding the 2022 Annual Meeting of the Bank's shareholders.

A. The Board has approved the following resolutions:

- (1) To approve the 2022 Annual Report and the 2022 Financial Statements.
- (2) To approve the 2022 Annual Report and the 2022 Financial Statements.
- (3) To approve the 2022 Annual Report and the 2022 Financial Statements, and to authorize the Board to approve the 2022 Annual Report and the 2022 Financial Statements.
- (4) To approve the 2022 Annual Report and the 2022 Financial Statements.
- (5) To approve the 2022 Annual Report and the 2022 Financial Statements.
- (6) To approve the 2022 Annual Report and the 2022 Financial Statements.
- (7) To approve the 2022 Annual Report and the 2022 Financial Statements.
- (8) To approve the 2022 Annual Report and the 2022 Financial Statements.
- (9) To approve the 2022 Annual Report and the 2022 Financial Statements.

A. The Board has approved the following resolutions:

- (10) To approve the 2022 Annual Report and the 2022 Financial Statements.
- (11) To approve the 2022 Annual Report and the 2022 Financial Statements.
- (12) To approve the 2022 Annual Report and the 2022 Financial Statements.

## 2. MATTERS TO BE CONSIDERED AT THE ANNUAL GENERAL MEETING

### i. 2022 Work Report of the Board of Directors

The Board has approved the 2022 Annual Report and the 2022 Financial Statements for presentation at the 2022 Annual Meeting of the Bank's shareholders.

The 2022 Annual Report and the 2022 Financial Statements will be available to all shareholders of the Bank on or before the date of the Annual Meeting, which is scheduled for September 29, 2023.

---

## LETTER FROM THE BOARD

---

**ii. 2022 Work Report of the Supervisory Committee**

The Supervisory Committee has reviewed the 2022 Work Report of the Supervisory Committee, which was approved by the Board of Supervisors on December 29, 2023. The Board of Supervisors has also reviewed the 2022 Work Report of the Supervisory Committee, which was approved by the Board of Supervisors on December 29, 2023.

**iii. 2022 Annual Report and its Summary, H Shares Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report**

The Board of Supervisors has reviewed the 2022 Annual Report and its Summary, H Shares Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report, which were approved by the Board of Supervisors on December 29, 2023. The Board of Supervisors has also reviewed the 2022 Annual Report and its Summary, H Shares Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report, which were approved by the Board of Supervisors on December 29, 2023.

**iv. 2022 Final Financial Report**

The Board of Supervisors has reviewed the 2022 Final Financial Report, which was approved by the Board of Supervisors on December 29, 2023. The Board of Supervisors has also reviewed the 2022 Final Financial Report, which was approved by the Board of Supervisors on December 29, 2023.

**v. 2022 Profit Distribution Proposal**

The Board of Supervisors has reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Supervisors on December 31, 2022 (the "Final Dividend"). The Board of Supervisors has also reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Supervisors on December 31, 2022.

The Board of Supervisors has reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Supervisors on December 31, 2022. The Board of Supervisors has also reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Supervisors on December 31, 2022.

---

## LETTER FROM THE BOARD

---

### vi. Re-appointment of auditors of the Company

The Board of Directors (the "Board") of the Company has reviewed the audit reports of the independent member auditors of the Company, PricewaterhouseCoopers ("PwC") and its member audit firms for the financial year ended 2023, and the Board has resolved to re-appoint PwC as the independent member auditors of the Company for the financial year ended 2024.

The Board also resolved to re-appoint the independent member auditors of the Company, PwC and its member audit firms, for the financial year ended 29, 2023. A resolution on the re-appointment of PwC and its member audit firms as the independent member auditors of the Company for the financial year ended 29, 2023, was passed by the Board.

### vii. Election of the sixth session of the Board

The Board of Directors (the "Board") of the Company has reviewed the proposal of the independent member auditors of the Company, PwC and its member audit firms for the financial year ended 2023, and the Board has resolved to re-appoint PwC as the independent member auditors of the Company for the financial year ended 29, 2023. A resolution on the re-appointment of PwC and its member audit firms as the independent member auditors of the Company for the financial year ended 29, 2023, was passed by the Board. ( **Mr. Li** ), ( **Ms. Li** ) ( **Mr. Shan** ) ( **Dr. Lu** ) ( **Mr. Zhang** ) ( **Mr. Huang** ) ( **Mr. Yi** ) A1 14 1.8 ( )1.7 ( )12.8 ( )A



---

## LETTER FROM THE BOARD

---

1. The Board has reviewed the financial performance of the Company for the period ended 31 December 2014. The Board is pleased to announce the following results of the Company for the period ended 31 December 2014:

3.4. As at 31 December 2014, the Company's total assets were HK\$1,235,700,000, representing an increase of 18.4% from HK\$1,043,800,000 as at 31 December 2013. The total liabilities of the Company as at 31 December 2014 were HK\$1,000,000,000, representing a decrease of 14.5% from HK\$1,162,500,000 as at 31 December 2013. The net assets of the Company as at 31 December 2014 were HK\$235,700,000, representing an increase of 14.8% from HK\$205,300,000 as at 31 December 2013. The Company's total assets less total liabilities were HK\$235,700,000, representing an increase of 14.8% from HK\$205,300,000 as at 31 December 2013. The Company's total assets less total liabilities were HK\$235,700,000, representing an increase of 14.8% from HK\$205,300,000 as at 31 December 2013.

A copy of the audited financial statements of the Company for the period ended 31 December 2014 is available on the Company's website at [www.sincere.com.hk](http://www.sincere.com.hk).

### **viii. Remuneration of independent non-executive Directors of the sixth session of the Board**

The remuneration of independent non-executive Directors of the sixth session of the Board for the period ended 31 December 2014 is as follows:

Name	Remuneration (HK\$)
Mr. Ho Yee-chung	100,000
Mr. Tang Chiu-chung	100,000
Mr. Wang Chiu-chung	100,000
Mr. Wong Chiu-chung	100,000
Mr. Wong Chiu-chung	100,000

### **ix. Election of the sixth session of the Supervisory Committee**

At the 184th Annual General Meeting of the Company held on 10 October 2014, the shareholders elected the following independent non-executive Directors to the sixth session of the Board:

( Mr. Zheng )

( Ms. Tang )

---

## LETTER FROM THE BOARD

---

董事鄭澤輝先生(鄭澤輝), 45歲, 現年53, 於2006年加入本公司。彼於1992年畢業於香港中文大學, 獲文學士學位。彼於2011年獲委任為本公司董事。

董事唐海均先生(唐海均), 44歲, 現年44, 於2001年加入本公司。彼於2007年獲委任為本公司董事。彼於2014年獲委任為本公司董事。

董事A先生, 現年A, 於A年加入本公司。彼於A年獲委任為本公司董事。彼於A年獲委任為本公司董事。

董事B先生, 現年B, 於B年加入本公司。彼於B年獲委任為本公司董事。彼於B年獲委任為本公司董事。

董事C先生, 現年C, 於C年加入本公司。彼於C年獲委任為本公司董事。彼於C年獲委任為本公司董事。

董事D先生, 現年D, 於D年加入本公司。彼於D年獲委任為本公司董事。彼於D年獲委任為本公司董事。

董事E先生, 現年E, 於E年加入本公司。彼於E年獲委任為本公司董事。彼於E年獲委任為本公司董事。

---

## LETTER FROM THE BOARD

---

x. **Purchase of Wealth Management Products and Cash Flow Management Using Internal Funds**

The Board has approved the purchase of wealth management products and cash flow management using internal funds for the period from January 1, 2023, to December 31, 2023.

The Board has also approved the purchase of wealth management products and cash flow management using internal funds for the period from January 1, 2023, to December 31, 2023.

xi. **Application for Credit Line and Providing Guarantee to Certain Banks for 2023**

The Board has approved the application for a credit line and providing a guarantee to certain banks for the period from January 1, 2023, to December 31, 2023.

The Board has also approved the application for a credit line and providing a guarantee to certain banks for the period from January 1, 2023, to December 31, 2023.

xii. **Amendment of Articles of Association**

The Board has approved the amendment of the Articles of Association for the period from January 1, 2023, to December 31, 2023.

The Board has also approved the amendment of the Articles of Association for the period from January 1, 2023, to December 31, 2023.

3. **ANNUAL GENERAL MEETING AND CLOSURE OF REGISTER OF MEMBERS OF H SHARES**

The Board has approved the annual general meeting and the closure of the register of members of H shares for the period from January 1, 2023, to December 31, 2023.

---

## LETTER FROM THE BOARD

---

... 17/ ... 16 ... 24 ...  
A

... 17, 2023 ... 22, 2023 (...  
...), ... A ...  
... 17/ ... 16 ... 4:30 ...  
16, 2023. ...  
22, 2023 ... A

... 29, 2023 ... 31,  
2023, ...  
... 17/ ...  
... 16 ... 4:30 ... 25, 2023.  
... 31, 2023  
... 2022  
A

#### 4. VOTING BY POLL

... 13.39(4) ...  
A ... A

... A ... A ...  
... A ...  
... ( ) ...  
... ( ) ... A ... 20  
... 24 ...

---

## LETTER FROM THE BOARD

---

### 5. RECOMMENDATION

At the meeting of the Board of Directors of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. held on August 2, 2022, the Board of Directors discussed and approved the following resolution:

**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**

**Li Li**

Chairman

A ... A ...

**Non-independent Directors****(i) Mr. Li Li**

(李鋌), 59, ... 28 ... A ... 2012 ...

(ii) Ms. Li Tan

(李坦), 58, ... 28, ... A

A 1998. ... A 2007; ... ( ) 2014; 2010; A 2013; A 2015; A 2016.

( ) 1987 ... 2005.

A 922,391,179 A , 73.96% A A ( ) 408,041,280 A ( 99.00% 1.00% ); ( ) 474,029,899 A ( 99.00% 1.00% ); ( ) 40,320,000 A ( )

(iii) Mr. Shan Yu

(單宇), 62, 28

1998. 2000; 2007; 2009; 2009; 2010; 2013; A 2014.

1982 2005.

A 99% 46,425,600 A 38.88% 15,118,035 A 52,302,892 A 3.56%

(iv) Mr. Zhang Ping

(張平), 58, 1992 1998,

30. 2021. A 2022. A 2002. 2021

1988. 2002.

A A A A



A 呂川, 53, 1991, 1994, 1997, 2005, 2008, 2012, 2016, 2019. (A 300052) A 2008, 8128) 2008, 2009, 1733) 2010, 2016, 2011, 2014.

A 13.51(2)(a), 13.51(2)(b).

**Independent Non-Executive Directors**

*(v) Dr. Lu Chuan*

呂川 (呂川), 53, 1991, 1994, 1997, 2005, 2008, 2012, 2016, 2019.

1991, A 1994, 1997, A 2005, 2008, 2012, 2016, 2019. (A 300052) A 2008, 8128) 2008, 2009, 1733) 2010, 2016, 2011, 2014.

A . . . . .

**(vi) Mr. Huang Peng**

(黃鵬), 74, 1949, . . . . . 2003.  
 . . . . . 1995  
 . . . . . 1985.  
 1988, . . . . .  
 . . . . . (新時代企業家研究院) . . . . .  
 . . . . . A . . . . . A . . . . . ( . . . . .  
 . . . . . : 601890), . . . . . ( . . . . .  
 . . . . . : 301180), . . . . . ( . . . . .  
 . . . . . : 300819) . . . . . &  
 . . . . . ( . . . . . : 603828). . . . .

A . . . . .

**(vii) Mr. Yi Ming**

(易銘), 46, 1977, . . . . .  
 . . . . . A . . . . .  
 2002 . . . . . A . . . . .  
 . . . . . 2014.  
 . . . . . ( . . . . .) A . . . . .  
 . . . . . 2003 . . . . . 2012. . . . . (A . . . . .) A . . . . .  
 . . . . . 2013 . . . . . 2018. . . . . A . . . . . A . . . . .  
 . . . . . 2018. . . . .

A . . . . .





<b>Existing Provisions of the Articles of Association</b>	<b>Proposed Amendments to the Articles of Association</b>
<p>A ...</p> <p>( ... )</p> <p>E ...</p> <p>A ...</p> <p>A ...</p>	<p>A ...</p> <p>( ... )</p> <p>E ...</p> <p>A ...</p> <p>A ...</p>
<p><b>Article 150</b></p>	<p><b>Article 150</b></p>
<p><b>Article 156</b></p>	<p><b>Article 156</b></p>
<p><b>Article 158</b></p>	<p><b>Article 158</b></p>



---

## NOTICE OF THE 2022 ANNUAL GENERAL MEETING

---

### ORDINARY RESOLUTION

8. To approve the financial statements for the year ended 31 December 2021 and the directors' report and the auditors' report thereon;

### SPECIAL RESOLUTION

9. To approve the proposed amendments to the Memorandum and Articles of Association of the Company, as set out in the Special Resolution Notice, and to authorize the directors to take all such steps as may be necessary to give effect to the proposed amendments;

### ORDINARY RESOLUTIONS

10. To approve the proposed amendments to the Memorandum and Articles of Association of the Company, as set out in the Ordinary Resolution Notice, and to authorize the directors to take all such steps as may be necessary to give effect to the proposed amendments;
11. To approve the proposed amendments to the Memorandum and Articles of Association of the Company, as set out in the Ordinary Resolution Notice, and to authorize the directors to take all such steps as may be necessary to give effect to the proposed amendments:
- 11.01 To approve the proposed amendments to the Memorandum and Articles of Association of the Company, as set out in the Ordinary Resolution Notice, and to authorize the directors to take all such steps as may be necessary to give effect to the proposed amendments;
  - 11.02 To approve the proposed amendments to the Memorandum and Articles of Association of the Company, as set out in the Ordinary Resolution Notice, and to authorize the directors to take all such steps as may be necessary to give effect to the proposed amendments;
  - 11.03 To approve the proposed amendments to the Memorandum and Articles of Association of the Company, as set out in the Ordinary Resolution Notice, and to authorize the directors to take all such steps as may be necessary to give effect to the proposed amendments;
  - 11.04 To approve the proposed amendments to the Memorandum and Articles of Association of the Company, as set out in the Ordinary Resolution Notice, and to authorize the directors to take all such steps as may be necessary to give effect to the proposed amendments;

---

## NOTICE OF THE 2022 ANNUAL GENERAL MEETING

---

12. 审议《2022年度利润分配预案》的议案；
- 12.01 审议《2022年度利润分配预案》的议案；
- 12.02 审议《2022年度利润分配预案》的议案；
- 12.03 审议《2022年度利润分配预案》的议案；
13. 审议《2022年度利润分配预案》的议案；
- 13.01 审议《2022年度利润分配预案》的议案；
- 13.02 审议《2022年度利润分配预案》的议案；

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Li Li

Chairman

2023年1月20日



## NOTICE OF THE 2022 ANNUAL GENERAL MEETING

Notice:

1. The 2022 Annual General Meeting of the Shareholders of the Company will be held on Monday, 17, 2023 (Wednesday) at 4:30 PM in the Conference Room of the Company, 17F, 17th Floor, 114, Seonheon-ro, Songpa-gu, Seoul. The agenda of the meeting is as follows:
  - A. Approval of the 2022 Annual Report
  - B. Approval of the 2023 Business Plan
  - C. Approval of the 2023 Financial Budget
  - D. Approval of the 2023 Dividend Policy
  - E. Approval of the 2023 Executive Compensation Policy
  - F. Approval of the 2023 Board of Directors Composition
  - G. Approval of the 2023 Board of Directors Nomination Policy
  - H. Approval of the 2023 Board of Directors Election Policy
  - I. Approval of the 2023 Board of Directors Election Method
  - J. Approval of the 2023 Board of Directors Election System
  - K. Approval of the 2023 Board of Directors Election System
  - L. Approval of the 2023 Board of Directors Election System
2. The 2022 Annual Report of the Company will be published on Monday, 17, 2023 (Wednesday) at 4:30 PM in the Conference Room of the Company, 17F, 17th Floor, 114, Seonheon-ro, Songpa-gu, Seoul.
3. The 2023 Business Plan of the Company will be published on Monday, 17, 2023 (Wednesday) at 4:30 PM in the Conference Room of the Company, 17F, 17th Floor, 114, Seonheon-ro, Songpa-gu, Seoul.
4. The 2023 Financial Budget of the Company will be published on Monday, 17, 2023 (Wednesday) at 4:30 PM in the Conference Room of the Company, 17F, 17th Floor, 114, Seonheon-ro, Songpa-gu, Seoul.
5. The 2023 Dividend Policy of the Company will be published on Monday, 17, 2023 (Wednesday) at 4:30 PM in the Conference Room of the Company, 17F, 17th Floor, 114, Seonheon-ro, Songpa-gu, Seoul.
6. The 2023 Executive Compensation Policy of the Company will be published on Monday, 17, 2023 (Wednesday) at 4:30 PM in the Conference Room of the Company, 17F, 17th Floor, 114, Seonheon-ro, Songpa-gu, Seoul.
7. The 2023 Board of Directors Composition of the Company will be published on Monday, 17, 2023 (Wednesday) at 4:30 PM in the Conference Room of the Company, 17F, 17th Floor, 114, Seonheon-ro, Songpa-gu, Seoul.
8. The 2023 Board of Directors Nomination Policy of the Company will be published on Monday, 17, 2023 (Wednesday) at 4:30 PM in the Conference Room of the Company, 17F, 17th Floor, 114, Seonheon-ro, Songpa-gu, Seoul.
9. The 2023 Board of Directors Election Policy of the Company will be published on Monday, 17, 2023 (Wednesday) at 4:30 PM in the Conference Room of the Company, 17F, 17th Floor, 114, Seonheon-ro, Songpa-gu, Seoul.
10. The 2023 Board of Directors Election Method of the Company will be published on Monday, 17, 2023 (Wednesday) at 4:30 PM in the Conference Room of the Company, 17F, 17th Floor, 114, Seonheon-ro, Songpa-gu, Seoul.
11. The 2023 Board of Directors Election System of the Company will be published on Monday, 17, 2023 (Wednesday) at 4:30 PM in the Conference Room of the Company, 17F, 17th Floor, 114, Seonheon-ro, Songpa-gu, Seoul.

---

## NOTICE OF THE 2022 ANNUAL GENERAL MEETING

---

- (iii) *[Faint, illegible text]*

9. *[Faint, illegible text]*